GlassScriptPhysician profile
Neal Robert Goodbar
NPI 1386963684
$12,067.98
in general payments reported to CMS, 2019-2025
48 companies · $1,503 in 2025
The $1,503 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,532 · 2020: $1,668 · 2021: $1,958 · 2022: $1,745 · 2023: $1,980 · 2024: $1,682 · 2025: $1,503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,164.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,358.13 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,210.29 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $1,060.34 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,060.29 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,035.93 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $769.12 | 2019-2025 | Trintellix |
| Pfizer INC. | $717.52 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $636.27 | 2019-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $543.21 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $428.06 | 2019-2025 | Verquvo, Gardasil 9, Capvaxive |
| Amgen INC. | $316.40 | 2019-2024 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $281.48 | 2019-2025 | Xifaxan, Trulance |
| Axsome Therapeutics, INC. | $209.57 | 2022-2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $193.49 | 2021-2025 | |
| Allergan, INC. | $187.89 | 2019-2020 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $172.78 | 2022-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $143.97 | 2019-2024 | Xarelto |
| Phathom Pharmaceuticals, INC. | $126.30 | 2024-2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $122.62 | 2022 | |
| Amarin Pharma, INC. | $115.14 | 2020-2021 | |
| Exact Sciences Corporation | $111.71 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Corcept Therapeutics | $109.84 | 2024-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $108.49 | 2021-2023 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $108.16 | 2019-2022 | |
| Dexcom, INC. | $93.29 | 2021-2024 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $86.57 | 2020-2023 | Austedo Xr |
| Abbott Laboratories | $83.99 | 2022-2024 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $78.40 | 2022-2025 | Quviviq, Quviviq |
| Lundbeck LLC | $78.10 | 2023-2025 | Rexulti, Vyepti |
| Astellas Pharma US INC | $71.31 | 2019-2023 | Veozah |
| Abiomed | $54.11 | 2024-2025 | Impella |
| Hikma Pharmaceuticals USA | $51.57 | 2019-2021 | |
| Edwards Lifesciences Corporation | $47.84 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Eisai INC. | $44.11 | 2021 | |
| Tris Pharma INC | $42.49 | 2025 | Dyanavel Xr |
| Medtronic, INC. | $25.65 | 2024 | Intellis Adaptivestim |
| Inari Medical, INC. | $22.83 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Eyevance Pharmaceuticals LLC | $21.30 | 2021 | |
| Sanofi Pasteur INC. | $18.78 | 2019 | |
| Gilead Sciences, INC. | $18.24 | 2023 | |
| Impel Pharmaceuticals INC. | $15.11 | 2023 | Trudhesa |
| Phadia US INC. | $15.07 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.40 | 2020 | |
| Csl Behring | $13.48 | 2024 | Haegarda |
| Shire North American Group INC | $13.03 | 2019 | |
| Vistapharm, INC. | $11.78 | 2021 | |
| Promius Pharma LLC | $11.07 | 2019 | |
| Organon LLC | $8.46 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neal Goodbar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.